Federated Hermes Inc. Sells 2,261 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Federated Hermes Inc. decreased its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 10.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 20,032 shares of the company’s stock after selling 2,261 shares during the quarter. Federated Hermes Inc.’s holdings in Mineralys Therapeutics were worth $172,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. acquired a new position in shares of Mineralys Therapeutics during the 4th quarter worth approximately $41,000. SG Americas Securities LLC bought a new position in Mineralys Therapeutics during the fourth quarter worth $87,000. Cornercap Investment Counsel Inc. acquired a new position in shares of Mineralys Therapeutics in the fourth quarter valued at $191,000. Jump Financial LLC acquired a new position in shares of Mineralys Therapeutics in the third quarter valued at $311,000. Finally, Raymond James Financial Services Advisors Inc. bought a new position in shares of Mineralys Therapeutics in the third quarter valued at about $386,000. 84.46% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Lifesci Capital reiterated an “outperform” rating on shares of Mineralys Therapeutics in a research note on Tuesday, March 26th. The Goldman Sachs Group started coverage on Mineralys Therapeutics in a research report on Tuesday, April 2nd. They issued a “buy” rating and a $30.00 target price on the stock.

Insider Transactions at Mineralys Therapeutics

In related news, major shareholder Samsara Biocapital Gp, Llc purchased 555,555 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was acquired at an average cost of $13.50 per share, for a total transaction of $7,499,992.50. Following the completion of the purchase, the insider now owns 5,074,916 shares in the company, valued at approximately $68,511,366. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 33.24% of the company’s stock.

Mineralys Therapeutics Stock Performance

MLYS opened at $12.95 on Monday. The stock has a fifty day moving average of $13.03 and a 200-day moving average of $10.53. The company has a market capitalization of $642.71 million, a P/E ratio of -6.48 and a beta of 2.05. Mineralys Therapeutics, Inc. has a fifty-two week low of $5.85 and a fifty-two week high of $17.70.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.61) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.24. On average, equities research analysts predict that Mineralys Therapeutics, Inc. will post -2.44 earnings per share for the current fiscal year.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.